TWI725937B - ω-３組成物、劑型及使用方法 - Google Patents
ω-３組成物、劑型及使用方法 Download PDFInfo
- Publication number
- TWI725937B TWI725937B TW104118318A TW104118318A TWI725937B TW I725937 B TWI725937 B TW I725937B TW 104118318 A TW104118318 A TW 104118318A TW 104118318 A TW104118318 A TW 104118318A TW I725937 B TWI725937 B TW I725937B
- Authority
- TW
- Taiwan
- Prior art keywords
- dosage form
- scope
- patent application
- item
- group
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title abstract description 67
- 238000000034 method Methods 0.000 title abstract description 62
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 44
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 25
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 54
- 239000000194 fatty acid Substances 0.000 claims description 54
- 229930195729 fatty acid Natural products 0.000 claims description 54
- 150000004665 fatty acids Chemical class 0.000 claims description 52
- 239000003921 oil Substances 0.000 claims description 39
- 235000019198 oils Nutrition 0.000 claims description 39
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 30
- 241000238366 Cephalopoda Species 0.000 claims description 25
- 125000004494 ethyl ester group Chemical group 0.000 claims description 19
- 239000010775 animal oil Substances 0.000 claims description 15
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 14
- 235000021323 fish oil Nutrition 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 8
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 6
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 4
- 230000000284 resting effect Effects 0.000 claims description 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 4
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 26
- 239000000902 placebo Substances 0.000 description 33
- 229940068196 placebo Drugs 0.000 description 33
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 32
- 125000004185 ester group Chemical group 0.000 description 25
- 101710095342 Apolipoprotein B Proteins 0.000 description 21
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 230000008859 change Effects 0.000 description 16
- 235000020925 non fasting Nutrition 0.000 description 13
- 230000008569 process Effects 0.000 description 12
- 239000004006 olive oil Substances 0.000 description 11
- 235000008390 olive oil Nutrition 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 241000251468 Actinopterygii Species 0.000 description 8
- 108090001030 Lipoproteins Proteins 0.000 description 8
- 102000004895 Lipoproteins Human genes 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000004202 carbamide Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000003205 diastolic effect Effects 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- -1 diglycerides Chemical class 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000004061 bleaching Methods 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940115970 lovaza Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 101710105047 Lipoprotein B Proteins 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000199 molecular distillation Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 108010079522 solysime Proteins 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462009145P | 2014-06-06 | 2014-06-06 | |
| US62/009,145 | 2014-06-06 | ||
| US201462019289P | 2014-06-30 | 2014-06-30 | |
| US62/019,289 | 2014-06-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201613571A TW201613571A (en) | 2016-04-16 |
| TWI725937B true TWI725937B (zh) | 2021-05-01 |
Family
ID=54767418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104118318A TWI725937B (zh) | 2014-06-06 | 2015-06-05 | ω-３組成物、劑型及使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9675575B2 (https=) |
| EP (2) | EP3906920A1 (https=) |
| JP (2) | JP6755186B2 (https=) |
| KR (1) | KR102400958B1 (https=) |
| CN (1) | CN106687113B (https=) |
| AU (1) | AU2015269307C1 (https=) |
| BR (1) | BR112016028561A8 (https=) |
| CA (1) | CA2950344C (https=) |
| CL (1) | CL2016003131A1 (https=) |
| MX (1) | MX2016015791A (https=) |
| MY (1) | MY186566A (https=) |
| RU (1) | RU2741965C2 (https=) |
| TW (1) | TWI725937B (https=) |
| WO (1) | WO2015188046A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10709680B2 (en) * | 2011-07-18 | 2020-07-14 | Physicians Recommended Nutriceuticals, Llc | Methods for treating dry eye |
| EP3906920A1 (en) * | 2014-06-06 | 2021-11-10 | Marine Ingredients, LLC | Omega-3 compositions, dosage forms, and methods of use |
| CN110958731A (zh) | 2018-09-21 | 2020-04-03 | 鸿盛国际有限公司 | 发光二极管并联电路 |
| FR3103355B1 (fr) | 2019-11-26 | 2024-05-31 | Polaris | Composition d’huile de micro-organismes enrichie en acides gras polyinsaturés |
| FR3151183A1 (fr) | 2023-07-20 | 2025-01-24 | Microphyt | Nouvelle utilisation d’un extrait de la microalgue Phaeodactylum tricornutum |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| FR2731015B1 (fr) | 1995-02-24 | 1997-05-30 | Sci Sartone | Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus |
| CA2236089C (en) * | 1995-11-24 | 2002-03-05 | Loders-Croklaan B.V. | Composition based on fish oil |
| US7799365B2 (en) * | 2001-04-06 | 2010-09-21 | Burnbrae Farms Limited | Liquid egg composition including fish oil with omega-3 fatty acid |
| US7169385B2 (en) * | 2003-09-29 | 2007-01-30 | Ronald G. Udell | Solubilized CoQ-10 and carnitine |
| SE0303513D0 (sv) | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| US20070020340A1 (en) * | 2005-07-25 | 2007-01-25 | David Rubin | Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension |
| CA2625338A1 (en) | 2005-10-07 | 2007-06-14 | Ocean Nutrition Canada Ltd. | Salts of fatty acids and methods of making and using thereof |
| CA2634139C (en) | 2005-12-20 | 2015-06-23 | Cenestra, Llc. | Omega 3 fatty acid formulations |
| EP1962825B1 (en) | 2005-12-21 | 2014-04-02 | Brudy Technology, S.L. | Use of dha for treating a pathology associated with cellular oxidative damage |
| CN101472490A (zh) | 2006-06-23 | 2009-07-01 | 宝洁公司 | 浓缩型ω-3脂肪酸以及包含它们的混合物 |
| WO2008036353A2 (en) | 2006-09-19 | 2008-03-27 | The Trustees Of Columbia University In The City Of New York | Omega-3 diglyceride emulsions |
| CA2685272A1 (en) * | 2007-04-26 | 2008-11-06 | Patrick Adlercreutz | A polyunsaturated fatty acid (pufa) enriched marine oil comprising eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), and a process of production thereof |
| US20100119600A1 (en) | 2007-06-01 | 2010-05-13 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
| CL2008002020A1 (es) | 2007-07-12 | 2008-11-14 | Ocean Nutrition Canada Ltd | Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite. |
| EP2172558B1 (en) * | 2007-07-30 | 2017-07-19 | Nippon Suisan Kaisha, Ltd. | Method for production of epa-enriched oil and dha-enriched oil |
| KR101045397B1 (ko) | 2008-07-04 | 2011-06-30 | 주식회사동우산업 | 오메가-3 지방산 함량이 높은 정제 오징어유의 제조방법 |
| GB0813599D0 (en) | 2008-07-24 | 2008-09-03 | Pharma Marine As | Method |
| RS53694B1 (sr) * | 2008-08-07 | 2015-04-30 | Spa Societa' Prodotti Antibiotici S.P.A. | Dugoročno lečenje simptomatske srčane insuficijencije |
| US20100236137A1 (en) * | 2008-09-23 | 2010-09-23 | LiveFuels, Inc. | Systems and methods for producing eicosapentaenoic acid and docosahexaenoic acid from algae |
| WO2010119319A1 (en) * | 2009-03-09 | 2010-10-21 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof |
| CN101695487B (zh) * | 2009-09-22 | 2012-01-18 | 北京百慧生化制药有限责任公司 | 一种高纯度epa-e、dha-e的多烯酸乙酯乳剂 |
| FR2955459B1 (fr) | 2010-01-28 | 2013-11-22 | Polaris | Composition huileuse riche en monoglycerides de dha |
| US20110223246A1 (en) * | 2010-03-10 | 2011-09-15 | Joar Opheim | Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source |
| US9675572B2 (en) | 2010-04-23 | 2017-06-13 | The United States Of America As Represented By The Secretary Of The Army | Intravenous omega-3 fatty acid compositions and method of use |
| EP2619298B1 (en) * | 2010-09-24 | 2018-09-12 | Pronova BioPharma Norge AS | Process for concentrating omega-3 fatty acids |
| US20120252888A1 (en) * | 2011-03-29 | 2012-10-04 | Palupa Medical Ltd. | Compositions and Methods for Treating Neurologic Disorders |
| US20140335061A1 (en) * | 2011-12-08 | 2014-11-13 | Metaproteomics, Llc | Supplemented oil compositions and methods for improved health |
| EP2793867B1 (en) * | 2011-12-22 | 2021-01-20 | Baes, Erik | Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof |
| DK2858496T3 (da) | 2012-05-10 | 2023-07-24 | Solutex Na Llc | Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere |
| WO2014057362A2 (en) | 2012-09-24 | 2014-04-17 | Aker Biopharma As | Omega -3 compositions |
| US20130310457A1 (en) | 2013-07-25 | 2013-11-21 | Niral Ramesh | Solid-in-oil dispersions |
| EP3906920A1 (en) | 2014-06-06 | 2021-11-10 | Marine Ingredients, LLC | Omega-3 compositions, dosage forms, and methods of use |
-
2015
- 2015-06-05 EP EP21157298.7A patent/EP3906920A1/en not_active Ceased
- 2015-06-05 MY MYPI2016704514A patent/MY186566A/en unknown
- 2015-06-05 CN CN201580030195.7A patent/CN106687113B/zh active Active
- 2015-06-05 MX MX2016015791A patent/MX2016015791A/es unknown
- 2015-06-05 KR KR1020167034160A patent/KR102400958B1/ko active Active
- 2015-06-05 CA CA2950344A patent/CA2950344C/en active Active
- 2015-06-05 RU RU2016149416A patent/RU2741965C2/ru active
- 2015-06-05 TW TW104118318A patent/TWI725937B/zh active
- 2015-06-05 BR BR112016028561A patent/BR112016028561A8/pt not_active IP Right Cessation
- 2015-06-05 EP EP15803689.7A patent/EP3151826A4/en not_active Ceased
- 2015-06-05 JP JP2016569985A patent/JP6755186B2/ja active Active
- 2015-06-05 WO PCT/US2015/034372 patent/WO2015188046A1/en not_active Ceased
- 2015-06-05 AU AU2015269307A patent/AU2015269307C1/en active Active
-
2016
- 2016-05-04 US US15/146,680 patent/US9675575B2/en active Active
- 2016-12-05 CL CL2016003131A patent/CL2016003131A1/es unknown
-
2017
- 2017-05-19 US US15/600,124 patent/US10034849B2/en active Active
-
2018
- 2018-06-29 US US16/023,904 patent/US10172819B2/en active Active
-
2019
- 2019-01-04 US US16/240,534 patent/US11160777B2/en active Active
-
2020
- 2020-04-06 JP JP2020068334A patent/JP2020105224A/ja active Pending
Non-Patent Citations (4)
| Title |
|---|
| Am J Clin Nutr 1990,52,p.632-639 * |
| Am J Clin Nutr 1990,52,p.632-639。 |
| Prostaglands,Leukotrienes and Essential Fatty Acids,83(2010),p.137-141 * |
| Prostaglands,Leukotrienes and Essential Fatty Acids,83(2010),p.137-141。 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11160777B2 (en) | Omega-3 compositions, dosage forms, and methods of use | |
| Calviello et al. | Low-dose eicosapentaenoic or docosahexaenoic acid administration modifies fatty acid composition and does not affect susceptibility to oxidative stress in rat erythrocytes and tissues | |
| JP2020050675A (ja) | 認知機能改善および心拍数低下のための方法 | |
| UA76108C2 (en) | Use of therapeutic combination of fatty acids | |
| JP6953504B2 (ja) | エイコサペンタエン酸アルキルエステルを含有する組成物及びその製造方法 | |
| JP2008525392A (ja) | Ｅｐａによる重度のメランコリー型うつ病の治療 | |
| JP6663993B2 (ja) | 安定性が向上し、取り込みが改善されたホノキオール及びマグノロール製剤、並びにそれらの使用方法 | |
| JPH04290822A (ja) | アレルギー予防薬および食品 | |
| CN102302155B (zh) | 云南大叶种茶树籽油软胶囊 | |
| JP2020182497A (ja) | 一価不飽和脂肪酸組成物およびアテローム性動脈硬化症を処置するための使用 | |
| JP2018104372A (ja) | クリルオイルと魚油とシソ油とを含有する組成物 | |
| CN106459833A (zh) | 源自水产物的游离一元不饱和脂肪酸或其低级醇酯的制造方法 | |
| JP4904751B2 (ja) | 生体内ｄｈａ合成促進剤 | |
| ITUB20153877A1 (it) | Metodo di purificazione di gliceridi di acidi grassi, composizioni che ne derivano, e loro uso | |
| JP6787891B2 (ja) | コミュニケーションスキルの改善のためのリン脂質調製物 | |
| Funk Ms | Select Dietary Fatty Acids Modulate Brain Long Chain Omega-3 and Omega-6 PUFA Content in Mice | |
| BR112020026069B1 (pt) | Composição de lipídio à base de vegetais, uso da mesma, composição nutracêutica, produto alimentício para consumo humano ou animal, e, processo para produzir uma composição de lipídio à base de vegetais | |
| UA124828U (uk) | Купажована рослинна олія | |
| WO1987007263A1 (fr) | Composition contenant un compose de l'acide linolenique | |
| JP2002193798A (ja) | ナチュラルキラー細胞活性化剤 | |
| JPH07216382A (ja) | トコフェロール強化精製エゴマ油、それを含有する脂肪輸液剤及び経口投与製剤 | |
| JP2007297395A (ja) | 高吸収性コエンザイムｑ１０組成物及びその製造方法 |